Related Experiment Video
Updated: Sep 16, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.1K
Systemic Biologic Treatment for Psoriasis in Elderly Patients.
Sapir Glazer Levavi1, Ronny Maman2, Shany Sherman1,2
1Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petach Tikva 49100, Israel.
Journal of Clinical Medicine
|July 12, 2025
Summary
Biologic drugs are effective and safe for treating psoriasis in elderly patients. Some treatments, like adalimumab and guselkumab, showed better drug survival when started after age 65.
Area of Science:
- Dermatology
- Geriatric Medicine
- Pharmacology
Background:
- Psoriasis affects a notable percentage of individuals over 60.
- Elderly patients are often excluded from clinical trials, limiting data on biologic efficacy and safety in this demographic.
Purpose of the Study:
- To evaluate the efficacy and safety of biologic drugs for psoriasis treatment in elderly patients.
- To compare outcomes between patients initiating biologic treatment before and after age 65.
Main Methods:
- Retrospective cohort study involving 149 elderly psoriasis patients.
- Patients were stratified into two groups: <65 years (adult-start) and >65 years (elderly-start).
- Analysis included patient characteristics, drug survival, and safety outcomes (hospitalizations for infection, death).
Main Results:
- Demographics, comorbidities, and treatment turnover were comparable between groups.
- Adalimumab (first-line) and guselkumab (any sequence) demonstrated significantly better drug survival in the elderly-start group.
- No significant differences in drug safety, including hospitalizations for infection or mortality, were observed between groups.
Conclusions:
- Biologic therapies are both efficacious and safe for managing psoriasis in the elderly population.
- Certain biologic agents, specifically adalimumab and guselkumab, may offer improved drug survival when initiated in patients over 65.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
237
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
237
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
272
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
272
01:29Inflammatory Bowel Disease IV: Pharmacological Management
198
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
198
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
204
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
204
01:24Nephrotic Syndrome III : Nursing Management
48
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
48
01:26Nephrotic Syndrome II : Assessment and Medical Management
23
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
23